FALLS CHURCH, Va.--(BUSINESS WIRE)--Response Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing therapies for weight management and metabolic health in high-need populations, today announced that data from its Phase 1b clinical trial evaluating RDX-002 in subjects receiving olanzapine will be presented at the American Psychiatric Association (APA) 2026 Annual Meeting, taking place May 16-20 in San Francisco, CA. RDX-002 is the company’s investigational, first-in-class, gut-restricted small molecule inhibitor of intestinal microsomal triglyceride transfer protein (iMTP), the protein responsible for packaging dietary fat and cholesterol into chylomicrons for absorption into the body. RDX-002 is in development for the prevention of antipsychotic-induced weight gain (AIWG).